Drugs / SCD411
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07501052 | May 2026 | diabetic macular edema, retinal vein occlusion, wet macular degeneration | Sam Chun Dang Pharm. Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04480463 | Aug 2020 → Sep 2022 | wet macular degeneration | Sam Chun Dang Pharm. Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCD411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07501052 ↗ |
| Action | Inhibit | “SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug.” NCT04480463 ↗ |
| Route | Intravitreal | “IVT (intravitreal) injection” NCT04480463 ↗ |